Infant mortality in the U.S. has increased by 7% since the 2022 Dobbs v. Jackson U.S. Supreme Court decision overturned the ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 8 includes Lara Exploration, Imperial Oil, Avino ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Check Out Our Latest Analysis on BHVN Biohaven Stock Performance Shares of NYSE:BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm ...

Get Our Latest Research Report on Biohaven Biohaven Price Performance Biohaven stock opened at $38.30 on Friday. The firm’s 50-day moving average is $39.65 and its two-hundred day moving average ...

The $59,746,277 settlement resolves a federal court case that Connecticut and 37 other states and Puerto Rico had joined against Biohaven Pharmaceutical Holding Company Ltd., a Pfizer-owned local ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

Viral sicknesses have risen in early 2025 amid the ongoing “quad-demic” in the U.S., referring to three respiratory viruses and one gastrointestinal disease, according to the Centers for ...

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...

“This is only the fifth time in 14 years we have seen such a large one-month rise (one percentage point or more) in year-ahead inflation expectations,” survey director Joanne Hsu noted in a ...